Inclusion of nonrandomized studies of interventions in systematic reviews of interventions: updated guidance from the Agency for Health Care Research and Quality Effective Health Care program

被引:15
作者
Saldanha, Ian J. [1 ]
Adam, Gaelen P. [1 ]
Banez, Lionel L. [2 ]
Bass, Eric B. [3 ]
Berliner, Elise [4 ]
Devine, Beth [5 ]
Hammarlund, Noah [6 ]
Jain, Anjali [2 ]
Norris, Susan L. [7 ]
Skelly, Andrea C. [8 ,9 ]
Vander Ley, Kelly [10 ]
Wang, Zhen [11 ]
Wilt, Timothy J. [12 ]
Viswanathan, Meera [13 ]
机构
[1] Brown Univ, Ctr Evidence Synth Hlth, Dept Hlth Serv Policy & Practice, Dept Epidemiol,Sch Publ Hlth, Providence, RI USA
[2] Agcy Healthcare Res & Qual, Evidence Based Practice Ctr Program, Ctr Evidence & Practice Improvement, Rockville, MD USA
[3] Johns Hopkins Sch Med, Dept Med, Baltimore, MD USA
[4] Cerner Enviza Inc, Kansas City, MO USA
[5] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Sch Pharm, Seattle, WA USA
[6] Univ Florida, Dept Hlth Serv Res Management & Policy, Gainesville, FL USA
[7] Oregon Hlth & Sci Univ, Portland, OR USA
[8] Pacific Northwest Evidence Based Practice Ctr, Portland, OR USA
[9] Aggregate Analyt Inc, Fircrest, WA USA
[10] Oregon Hlth & Sci Univ, Dept Med & Clin Informat & Clin Epidemiol, Portland, OR USA
[11] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA
[12] Univ Minnesota, Minneapolis VA Ctr Care Delivery & Outcomes Res, Sch Med & Publ Hlth, Minneapolis, MN USA
[13] RTI Int, Res Triangle Pk, NC USA
基金
美国医疗保健研究与质量局;
关键词
Systematic reviews; Nonrandomized studies; Study eligibility; Guidance; Interventions; Effectiveness; DESIGNS;
D O I
10.1016/j.jclinepi.2022.08.015
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objectives: We developed guidance to inform decisions regarding the inclusion of nonrandomized studies of interventions (NRSIs) in systematic reviews (SRs) of the effects of interventions.Study Design and Setting: The guidance workgroup comprised SR experts and used an informal consensus generation method. Results: Instead of recommending NRSI inclusion only if randomized controlled trials (RCTs) are insufficient to address the SR key question, different topics may require different decisions regarding NRSI inclusion. We identified important considerations to inform such decisions from topic refinement through protocol development. During topic scoping and refinement, considerations were related to the clinical decisional dilemma, adequacy of RCTs to address the key questions, risk of bias in NRSIs, and the extent to which NRSIs are likely to complement RCTs. When NRSIs are included, during SR team formation, familiarity with topic-specific data sources and advanced an-alytic methods for NRSIs should be considered. During protocol development, the decision regarding NRSI inclusion or exclusion should be justified, and potential implications explained. When NRSIs are included, the protocol should describe the processes for synthesizing evidence from RCTs and NRSIs and determining the overall strength of evidence.Conclusion: We identified specific considerations for decisions regarding NRSI inclusion in SRs and highlight the importance of flex-ibility and transparency.(c) 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http:// creativecommons.org/licenses/by/4.0/).
引用
收藏
页码:300 / 306
页数:7
相关论文
共 22 条
[1]   Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials [J].
Anglemyer, Andrew ;
Horvath, Hacsi T. ;
Bero, Lisa .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (04)
[2]  
[Anonymous], 2010, SELECTING OBSERVATIO
[3]   Evaluating agreement between bodies of evidence from randomized controlled trials and cohort studies in medical research: a meta-epidemiological study [J].
Brockelmann, Nils ;
Balduzzi, Sara ;
Harms, Louisa ;
Beyerbach, Jessica ;
Petropoulou, Maria ;
Kubiak, Charlotte ;
Wolkewitz, Martin ;
Meerpohl, Joerg J. ;
Schwingshackl, Lukas .
BMC MEDICINE, 2022, 20 (01)
[4]  
Celentano D D., 2018, Gordis Epidemiology, V6TH
[5]  
Chou R, 2021, COMP EFFECTIVENESS R, V247
[6]  
Deeks J J, 2003, Health Technol Assess, V7, piii
[7]   When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments? [J].
Franklin, Jessica M. ;
Platt, Richard ;
Dreyer, Nancy A. ;
London, Alex John ;
Simon, Gregory E. ;
Watanabe, Jonathan H. ;
Horberg, Michael ;
Hernandez, Adrian ;
Califf, Robert M. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 (01) :108-115
[8]   Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies First Results From the RCT DUPLICATE Initiative [J].
Franklin, Jessica M. ;
Patorno, Elisabetta ;
Desai, Rishi J. ;
Glynn, Robert J. ;
Martin, David ;
Quinto, Kenneth ;
Pawar, Ajinkya ;
Bessette, Lily G. ;
Lee, Hemin ;
Garry, Elizabeth M. ;
Gautam, Nileesa ;
Schneeweiss, Sebastian .
CIRCULATION, 2021, 143 (10) :1002-1013
[9]   Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project [J].
Franklin, Jessica M. ;
Pawar, Ajinkya ;
Martin, David ;
Glynn, Robert J. ;
Levenson, Mark ;
Temple, Robert ;
Schneeweiss, Sebastian .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 (04) :817-826
[10]   Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making [J].
Franklin, Jessica M. ;
Glynn, Robert J. ;
Martin, David ;
Schneeweiss, Sebastian .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (04) :867-877